JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Guardant Health Inc

Fechado

SetorSaúde

114.32 0.77

Visão Geral

Variação de preço das ações

24h

Atual

Mín

112.28

Máximo

115.88

Indicadores-chave

By Trading Economics

Rendimento

7.2M

-93M

Vendas

33M

265M

Margem de lucro

-34.965

Funcionários

1,999

EBITDA

6.6M

-82M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+12.53% upside

Dividendos

By Dow Jones

Próximos Ganhos

19 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

5.9B

15B

Abertura anterior

113.55

Fecho anterior

114.32

Sentimento de Notícias

By Acuity

50%

50%

147 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Guardant Health Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de fev. de 2026, 23:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 de fev. de 2026, 23:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 de fev. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 de fev. de 2026, 23:38 UTC

Conversa de Mercado

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 de fev. de 2026, 23:28 UTC

Conversa de Mercado

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 de fev. de 2026, 23:23 UTC

Ganhos

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 de fev. de 2026, 22:57 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 de fev. de 2026, 22:08 UTC

Conversa de Mercado

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 de fev. de 2026, 21:51 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

2 de fev. de 2026, 21:49 UTC

Ganhos

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 de fev. de 2026, 21:39 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:36 UTC

Ganhos

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 de fev. de 2026, 21:34 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:28 UTC

Aquisições, Fusões, Aquisições de Empresas

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 de fev. de 2026, 21:23 UTC

Ganhos

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 de fev. de 2026, 21:19 UTC

Ganhos

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 de fev. de 2026, 21:17 UTC

Ganhos

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 de fev. de 2026, 21:17 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:10 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:08 UTC

Ganhos

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 de fev. de 2026, 21:07 UTC

Ganhos

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q Net $608.7M >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q Rev $1.41B >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q EPS 24c >PLTR

2 de fev. de 2026, 20:40 UTC

Conversa de Mercado

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparação entre Pares

Variação de preço

Guardant Health Inc Previsão

Preço-alvo

By TipRanks

12.53% parte superior

Previsão para 12 meses

Média 128.33 USD  12.53%

Máximo 175 USD

Mínimo 105 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Guardant Health Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

19 ratings

18

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

38.86 / 47.41Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

147 / 352 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat